Regeneron Reports registry Data for Cabotegravir in Hidradenitis suppurativa

Regeneron today announced registry results for cabotegravir in patients with hidradenitis suppurativa. The study demonstrated that cabotegravir demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of hidradenitis suppurativa and support the continued development of cabotegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.